Impeto Medical About Us

Impeto Medical devices: EZSCAN and SUDOSCAN



Impeto Medical

Sudoscan: Interview with
Alexander J. Smirnoff, neurologist

Activation of the sweat glands to detect small fiber nerves neuropathy


Newscast: Impeto Medical News

ADA booth

2016 Convention calendar

Impeto Medical participated in conventions related to diabetes, neuro, pharmacists, oncology and more ...
Read More

SUDOSCAN the European Congress on Hereditary Amyloidosis ATTR

SUDOSCAN at European Congress on Hereditary Amyloidosis ATTR ...
Read More

Impeto Medical – New patent for the US market

Impeto Medical got a new patent for the US market ...
Read More


A clinical study on diabetic neuropathy has been funded through FEDER (Fonds Européen de Développement Régional, European Regional Development Fund).

> Company profile

Impeto Medical has developed a patented technology that assesses sudomotor function through sweat gland activity. It is non-invasive and analyses the ability of sweat glands to release chloride ions in response to an electrochemical stimulus. Sweat conductances are then measured on the palms of the hands and the soles of the feet. The level of sweat gland activity is linked to the status of small nerve fibers innervating sweat glands. Small nerve neuropathy can be present in the early stages of diabetes and prediabetes.

Based on this technology, Impeto Medical has developed :

  • SUDOSCAN, a medical device for the early detection and follow-up of Peripheral Autonomic Neuropathies.
  • EZSCAN, a medical device for the early detection of Peripheral Autonomic Neuropathy in order to screen for subjects at higher risk of diabetes or prediabetes. It’s an alternative method for screening of risk.

> Our Mission

Impeto Medical* is a privately owned medical device company formed in June 2005. Its corporate headquarters are located in Paris, France. Two subsidiaries have been created: Beijing Impeto Medical in China and Impeto Medical Inc. in San Diego, U.S.

Our goal is to provide the medical community with screening tests to face epidemically spreading metabolic disorders and their complications. By providing less invasive, faster and less costly procedures, we enable physicians to screen larger patient populations and to detect diseases and complications earlier. We build value for our investors through constant innovation based on clinical research as well as focus on priority medical issues.